

Indoco's Profit Grows by 44%

May 28, 2014, Mumbai: Indoco Remedies Limited has recorded a total revenue growth of 15.8 % at ₹185.9 crores during the fourth quarter of FY 2013-14 as against ₹160.5 crores during the same period last year. For the year 2013-14, the net revenues grew by 14.5% at ₹717.4 Crs as against ₹626.4 Crs. EBIDTA to net sales for the quarter is 19.9 % at ₹37.0 Crs as against 17.4 % at ₹27.9 Crs during the same quarter last year and for the year, it is 18.7 % at ₹134.5 Crs as against 16.8 % at ₹105.4 Crs last year. Profit before tax (PBT) to net sales for the quarter is 12.1 % at ₹22.6 Crs as against 8.9% at ₹14.3 Crs during the same quarter last year. For the year, PBT is 10.1% at ₹72.1 Crs as against 7.7 % at ₹48.4 Crs last year.

Profit after tax (PAT) grew by 44.4% for the quarter and is 10.0 % of net sales at ₹18.5 Crs as against 8.0% at ₹12.8 Crs during the same quarter last year. For the year, PAT is 8.1% at ₹57.9 Crs as against 6.8 % at ₹42.7 Crs last year. The un-audited standalone results for the fourth quarter of the FY 2013-14 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2014.

Commenting on the performance, **Mr. Suresh G. Kare, Chairman** said, *"During the quarter, both Domestic as well as International Business segments of Indoco have registered good growth of 13.9% and 18.2% respectively. In the quarter, the Company received approval for its Goa sterile ophthalmic facility from EU Regulatory and also received the 'Best Patent Award 2012-2013' for two of its API process patents at the 52nd IDMA awards. These developments and our belief in our strategies, give us the confidence that the Company is moving faster in the right direction to meet its set goals".*

HIGHLIGHTS

For Fourth Quarter ended 31st March 2014 of FY 2013-14

Net Revenues at ₹ 185.9 crores

EBIDTA at ₹ 37.0 crores

Profit Before Tax at ₹ 22.6 crores

Profit After Tax at ₹ 18.5 crores

EPS at ₹ 2.01

For the Year ended 31st March 2014 of FY 2013-14

Net Revenues at ₹ 717.4 crores

EBIDTA at ₹ 134.5 crores

Profit Before Tax at ₹ 72.1 crores

Profit After Tax at ₹ 57.9 crores

EPS at ₹ 6.28

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with a global presence in 80 countries including USA and UK. Indoco, a USD 125 million Company, employs over 4500 people including 200 skilled scientists.

The Company has 8 manufacturing facilities, 5 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre. The facilities have been approved by UK-MHRA, USFDA, TGA-Australia, JAZMP-Slovenia, MCC-South Africa, Darmstadt – Germany, NDA-Uganda, TFDA-Tanzania, SBD-Yemen, MOH-Ukraine, PPB-Kenya, FDB-Ghana, etc. Indoco manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 2,00,000 doctors in India. Indoco's 8 domestic marketing divisions, viz., Indoco, Spade, Warren, Spera, Excel, Eterna, Indoco CND and Institution cater to both acute and chronic therapies. Indoco has a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infectives, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, etc. Top Indoco brands include Febrex Plus, Cyclopam, Sensodent-K, ATM, Glychek, Methycal, Rosuchek-D, Omegachek, Vepan, Cital, Oxipod, Sensoform, Osteochek, Lorchek-MR, Homide, Renolen, Cloben-G, Karvol Plus, Tuspel Plus, Inflachek-D, Clamchek and MCBM 69. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) - USA, ASPEN-South Africa and DSM-Austria.

Indoco Remedies Limited shares were listed in 2005 on BSE and NSE.

Other Details:

Face Value Of Equity Shares	₹ 2/-
Market Lot Of Equity Shares	1
BSE Code	532612
NSE Code	INDOCO EQ
ISIN:	INE873D01024

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com

Samir Daini

Mobile: 9820301130

E-mail: samir@indoco.com
